Table 2. NNRTI susceptibility of HIV-1 RT containing subunit specific mutations.
The concentrations of NNRTI required to inhibit the activity of purified RT by 50% (IC50) are reported as an average of three independent experiments±S.D. Values in parentheses indicate fold-resistance.
| IC50 | |||
|---|---|---|---|
| Efavirenz (nM) | Nevirapine (μM) | Delavirdine (μM) | |
| p66WT/p51WT | 15.44±3.16 (1.0) | 5.21±1.08 (1.0) | 1.68±0.50 (1.0) |
| p66I132M/p51I132M | 69.08±9.02 (4.6) | 44.80±4.26 (8.6) | 23.35±2.56 (13.9) |
| p66I132M/p51WT | 15.34±4.46 (1.0) | 5.20±1.05 (1.0) | 1.60±0.85 (1.0) |
| p66WT/p51I132M | 78.19±10.05 (5.2) | 47.93±6.36 (9.2) | 21.33±3.85 (12.7) |
| p66I135M/p51I135M | 32.11±1.09 (2.1) | 28.13±3.36 (5.4) | 3.02±0.45 (1.8) |
| p66I135M/p51WT | 15.37±8.02 (1.0) | 4.91±1.25 (0.9) | 1.70±0.55 (1.0) |
| p66WT/p51I132M | 35.36±1.19 (2.3) | 25.52±2.88 (4.9) | 3.86±0.35 (2.3) |
| p66E138K/p51E138K | 35.17±1.29 (2.3) | 11.46±2.77 (2.2) | 10.08±2.22 (6.0) |
| p66E138K/p51WT | 15.21±7.03 (1.0) | 5.00±1.10 (1.0) | 1.64±0.65 (1.0) |
| p66WT/p51E138K | 36.22±9.02 (2.4) | 12.50±3.20 (2.4) | 10.25±2.70 (6.1) |